Extension Program for Bay 43-9006
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Survival
Death
No
Bayer Study Director
Study Director
Bayer
United States: Food and Drug Administration
10922
NCT00657254
December 2002
June 2005
Name | Location |
---|---|
Boston, Massachusetts |